Angela Rankine-Mullings - MBBS
Senior Research FellowSome quote
Dr Angela Rankine-Mullings is a Paediatrician, Researcher and Senior Research Fellow at the Sickle Cell Unit, CAIHR with 30 years of experience working nationally and internationally including 13 years of experience in the management of sickle cell disease specifically in the area of hydroxyurea therapy and the prevention of paediatric sickle cell. She utilizes her wide multicultural and international experience to enrich her work at CAIHR. While at CAIHR, Dr Rankine-Mullings has participated in investigator-led and industry funded studies and has been at the forefront of clinical trials in hydroxyurea, including the NIH sponsored, SCATE (Sparing Conversion to Abnormal Transcranial Doppler velocity Elevation) trial (NCT01531387) and the EXTEND trial (NCT02556099), in collaboration with Cincinnati Children’s Hospital Medical Centre, which have advanced the use of hydroxyurea as a non-transfusion disease modifying therapy.
Dr Rankine-Mullings PhD work extends the understanding of vascular biology in children with sickle cell disease by examining arterial stiffness impairment in this population. Her PhD project furthers work in the prevention of neurologic injury in sickle cell disease and is focused on the topic: “Understanding the vascular biology underpinning the development of neurologic injury in sickle cell disease through Transcranial Doppler ultrasonography and arterial stiffness measurements in children with sickle cell disease”.
With respect to experience in the conduct of clinical trials, over the past 13 years, Dr Rankine-Mullings has worked as an investigator in the areas of hydroxyurea therapy and other sickle cell disease modifying therapies. Along with the members of an outstanding team she has provided technical and administrative management of these trials inclusive of full regulatory compliance from start-up to close-out, data management and dissemination of findings through publications and conference presentations.
Click here to download her full professional profile
Research & Teaching Interests
Her research focal areas include in part: (i) the prevention of neurologic injury in sickle cell disease (ii) Expansion of hydroxyurea use in sickle cell disease (iii) the effects of emerging infections in vulnerable populations. Additionally, Dr Rankine-Mullings seeks to prevent stroke in children with sickle cell anaemia through Transcranial Doppler screening and hydroxyurea treatment.
Training Programmes
Dr Rankine-Mullings is a lecturer in the Masters of Science (MSc) Programme in the areas of Nutrition and Epidemiology; The University of the West Indies.
Selected Publications
Rankine-Mullings A, Keenan R, Chakravorty S, Inusa B, Telfer P, Velangi M, Ware RE, Moss JJ, Lloyd AL, Edwards S, Mulla H. Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia, Blood Adv. 2023 Aug 22;7(16):4319-4322.
Rankine-Mullings AE, Logan TM, Asnani M, Serjeant GR. Early splenomegaly and septicaemia in homozygous sickle cell disease: A birth cohort study. Pediatr Blood Cancer. 2023 Mar;70(3):e30161. Rankine-Mullings AE, Nevitt SJ. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database of Systematic Reviews 2022, Issue 9. Art. No.: CD002202.
Rankine-Mullings AE. Ulcerative colitis in patients with sickle cell disease: a rare but important co-morbidity. Paediatr Int Child Health. 2022 Feb;42(1):1-4:
Rankine-Mullings A , Reid M, Soares D, Taylor-Bryan, C MB,BS, PhD, BSc, DM, Margaret Wisdom-Phipps, RN, RM, Karen Aldred, MSc, Teresa Latham, MA, Jennifer Knight-Madden, MB,BS, PhD, MB BS, Asha Badaloo, PhD, Adam Lane, PhD, Robert J. Adams, MD, MS and Russell E. Ware, MD, PhD. Hydroxyurea treatment reduces Transcranial Doppler (TCD) velocity in the absence of transfusion support in children with sickle cell anaemia, elevated TCD velocity, and cerebral vasculopathy: The EXTEND trial. Br J Haematol.2021 Nov;195(4):612-620.
Contact
Telephone
(876) 927-2471
angela.rankinemullings@uwimona.edu.jm
